FATE · NASDAQ
Fate Therapeutics (FATE) Stock Price & Fundamentals
Fate Therapeutics (FATE) closed at $492.95 on Oct 9, 2026, up 0.90% from the previous close of $488.53.
Share price, past year
1Y +12.15%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $492.95 |
| Sep 30, 2026 | $500.53 |
| Aug 31, 2026 | $464.97 |
| Jul 31, 2026 | $476.56 |
| Jun 30, 2026 | $488.75 |
| May 29, 2026 | $480.23 |
| Apr 30, 2026 | $456.31 |
| Mar 31, 2026 | $430.72 |
| Feb 27, 2026 | $465.01 |
| Jan 30, 2026 | $473.13 |
| Dec 31, 2025 | $472.70 |
| Nov 28, 2025 | $472.16 |
| Oct 31, 2025 | $444.59 |
Key statistics
- Market cap
- $57.52B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.05
- Revenue (TTM)
- $6.49M
- Net income (TTM)
- −$126.00M
- Shares outstanding
- 116.7M
- Dividend yield
- —
- 52-week range
- $427.67 – $502.05
Fate Therapeutics's market cap is $57.52B, based on a share price of $492.95 and 116.7M shares outstanding as of Jun 30, 2026.
Financials
Fate Therapeutics reported revenue of $6.65M for fiscal 2025, down 51.24% from fiscal 2024.
Fate Therapeutics reported a net loss of $136.32M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $6.65M | −51.2% | −$136.32M | −2,051.1% | −$1.15 | −$112.04M |
| FY2024ended Dec 31, 2024 | $13.63M | −78.6% | −$186.26M | −1,366.5% | −$1.64 | −$123.60M |
| FY2023ended Dec 31, 2023 | $63.53M | −34.0% | −$160.93M | −253.3% | −$1.64 | −$138.42M |
| FY2022ended Dec 31, 2022 | $96.30M | +72.4% | −$281.72M | −292.6% | −$2.91 | −$283.77M |
| FY2021ended Dec 31, 2021 | $55.85M | +77.7% | −$212.15M | −379.9% | −$2.24 | −$213.57M |
| FY2020ended Dec 31, 2020 | $31.43M | +194.3% | −$173.39M | −551.6% | −$2.10 | −$44.16M |
| FY2019ended Dec 31, 2019 | $10.68M | +125.3% | −$98.15M | −919.0% | −$1.44 | −$90.57M |
| FY2018ended Dec 31, 2018 | $4.74M | +15.4% | −$66.60M | −1,405.0% | −$1.19 | −$40.95M |
| FY2017ended Dec 31, 2017 | $4.11M | −6.7% | −$42.95M | −1,046.1% | −$1.02 | −$38.54M |
| FY2016ended Dec 31, 2016 | $4.40M | — | −$33.46M | −760.2% | −$1.05 | −$30.28M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $2.08M | −$30.16M | −$0.25 |
| Q1 FY2026ended Mar 31, 2026 | $1.30M | −$31.21M | −$0.26 |
| Q4 FY2025ended Dec 31, 2025 | $1.37M | −$32.37M | −$0.27 |
| Q3 FY2025ended Sep 30, 2025 | $1.74M | −$32.25M | −$0.27 |
| Q2 FY2025ended Jun 30, 2025 | $1.91M | −$34.07M | −$0.29 |
| Q1 FY2025ended Mar 31, 2025 | $1.63M | −$37.62M | −$0.32 |
| Q4 FY2024ended Dec 31, 2024 | $1.86M | −$52.15M | −$0.44 |
| Q3 FY2024ended Sep 30, 2024 | $3.07M | −$47.68M | −$0.40 |
Company profile
- Name
- Fate Therapeutics, Inc.
- Ticker
- FATE
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 12278 Scripps Summit Drive, San Diego, CA 92131
- Fiscal year ends
- December
- SEC CIK
- 0001434316
Recent SEC filings
- Sep 28, 2026
- Aug 13, 2026
- Aug 13, 2026
- Jun 15, 2026
- Jun 4, 2026
- May 13, 2026
- May 13, 2026
- Feb 26, 2026
Frequently asked questions
What is Fate Therapeutics's stock price?
Fate Therapeutics (FATE) closed at $492.95 on Oct 9, 2026, up 0.90% from the previous close of $488.53.
What is Fate Therapeutics's market cap?
Fate Therapeutics's market cap is $57.52B, based on a share price of $492.95 and 116.7M shares outstanding as of Jun 30, 2026.
How much revenue does Fate Therapeutics make?
Fate Therapeutics reported revenue of $6.65M for fiscal 2025, down 51.24% from fiscal 2024.
Does Fate Therapeutics pay a dividend?
Fate Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Fate Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures